Fresh articles published daily by PepBot's research engine. Deep dives, protocols, and the latest science.
YK-11 modulates myostatin and androgen receptor pathways to promote muscle growth and bone differentiation but carries potential neurochemical risks.
DHEA is linked to hormonal regulation and aging benefits. Increased DHEA levels after CPAP withdrawal highlight a stress-related mechanism [PMID: 42819394]. Frequent romantic partner touch in older adults associates with better metabolic and cardiovascular health, potentially involving DHEA [PMID: 42756988].
Discover the potential of GHRP-6 in promoting ghrelin signaling, enhancing appetite, and facilitating GH secretion, based on recent clinical and preclinical research.
Livagen, a synthetic tetrapeptide, has shown promising results in normalizing liver function and enhancing protein synthesis in animal models, particularly older ones. Its tissue-specific effects offer potential for age-related liver pathologies [PMID: 32362099][PMID: 15926314]. However, more research is needed to translate these findings into human applications.
GHRP-2, a growth hormone secretagogue, shows promise in urology and sexual medicine but lacks extensive long-term safety data. This article reviews key findings from recent studies.
Fisetin shows promise as a senolytic agent, with studies demonstrating its potential to eliminate senescent cells and enhance healthspan in aged models [PMID: 42836501]. However, despite progress in preclinical research, human trials lag in confirming these effects, highlighting a gap in current evidence [PMID: 42843464].
Retatrutide shows significant reductions in apnea-hypopnea index among obese adults with obstructive sleep apnea in Phase 3 trials [PMID: 42904878]. Its triple receptor agonist mechanism also offers potential benefits for weight management and metabolic health [PMID: 42745421, PMID: 42871568].
IGF-1 LR3 shows promising roles from muscle preservation to neural support. Investigate the biology, research boundaries, and frequently asked questions on this peptide's potential.
Thymosin Alpha-1 (Tα1) is gaining attention for its dual role in neuroprotection and immune modulation, notably in cancer therapy [PMID: 42693587, 42295795]. However, inconsistent safety reporting and limited study generalizability highlight the need for more rigorous research [PMID: 42797537, 42345155].
ACP-105, an experimental SARM, has emerged in research with significant implications for metabolism and doping detection.
GHK-Cu, a copper peptide, demonstrates promising potential in skin and tissue regeneration. While preclinical studies support its regenerative capabilities, clinical evidence remains limited [PMID: 42320090; PMID: 42887096; PMID: 42586657; PMID: 42058630].
Tirzepatide shows superior weight loss and cardiovascular outcomes compared to semaglutide among patients with T2D [PMID: 42840232, 42871568]. However, semaglutide remains a cost-effective choice in certain economic settings [PMID: 42894545].
SLU-PP-332, a novel ERR agonist, mimics exercise by enhancing mitochondrial metabolism and muscle adaptation, offering potential in treating metabolic and cardiovascular disorders [PMID: 41850449], [PMID: 41688415]. Its structural optimization improves selectivity and efficacy as revealed by SAR analysis [PMID: 41850449].
CJC-1295 and Ipamorelin are peptide compounds increasingly used in sports and medicine to stimulate growth hormone production, although their clinical effectiveness remains under-studied in human populations [PMID: 42862021; PMID: 42395176].
Recent studies highlight the therapeutic potential of mitochondrial peptides such as SS-31 and MOTS-c in addressing oxidative stress-related mitochondrial dysfunction across various conditions [PMID: 42600764, 42633281].
Discover how Ostarine (Enobosarm) has been studied in controlled trials and review its effects on muscle mass and potential therapeutic uses.
P21 plays a versatile role in cognitive functions and neural interventions. Exercise regulates p21 in the CNS, with outcomes on cognitive integrity [PMID: 42632465]. Formononetin shows promise in ameliorating cognitive decline in mice through p21 modulation [PMID: 42846323].
Survodutide, as a dual agonist targeting glucagon and GLP-1 receptors, shows promising results in managing obesity and metabolic disorders.
Testosterone therapies in transmasculine individuals and aromatase inhibitors (AIs) in male populations show varied physiological impacts. Individualized approaches are necessary to optimize results, which may not directly translate into broader physical or functional benefits [PMID: 42871731] [PMID: 42735742].
Epitalon and Khavinson Peptides show promise in aging modulation through telomere maintenance, oxidative stress reduction, and epigenetic remodeling [PMID: 42884164, PMID: 35413689, PMID: 37042594]. Despite the potential, robust clinical evidence remains sparse [PMID: 42884164].
PepBot can answer any question in real time — more detailed than any article.